Heidi McIntyre

TL;DR: Univariate analysis showed favorable trends for azacitidine compared with CCR across all subgroups defined by baseline demographic and disease features, and adverse events were consistent with the well-established safety profile of azacItidine.

TL;DR: The initial phase of this ongoing multicenter, community-based, open-label study evaluated three alternative AZA dosing schedules without weekend dosing, and results support AZA benefits in transfusion-dependent lower-risk MDS patients.

TL;DR: The results of the initial 6-cycle Tx phase demonstrate a consistent response for HI, RBC transfusion independence, and safety profile across a broad range of MDS pts, including FAB low-risk pts.

TL;DR: Determine effects of AZA vs CCR on OS, response, and safety in the subset of pts with AML-MDC in the AZA-AML-001 trial; and further analyze OS in AML -MDC pts who had been preselected to receive low-dose cytarabine (LDAC) before randomization to AZA or CCR.

TL;DR: The phase 3, multicenter, randomized, open-label AZA-AML-001 trial showed azacitidine Tx in older pts with newly diagnosed AML prolonged median OS by ~4 mos vs conventional care regimens (CCR) and improved 1-year survival (46.5% vs 34.2%) and Cytogenetic risk was balanced between Tx groups.